Loomis Sayles & Co L P 13F: Cuts Alkermes (ALKS) Stake by $6.2M

Loomis Sayles Adjusts Alkermes Holdings

Loomis Sayles & Co L P trimmed its stake in Alkermes plc (NasdaqGS: ALKS) during the period, according to its latest Form 13F filing with the Securities and Exchange Commission. The asset manager cut its position by 6.2%, selling 117,941 shares to wrap up the reporting window with 1,784,581 shares.

That remaining block of shares carried a total value of about $93.5 million at the close of the period. Institutional investors frequently adjust portfolio weightings for various risk management reasons, and this reduction follows similar moves by other large funds earlier in the year, such as JPMorgan Chase trimming over one million shares in a prior reporting cycle.

Alkermes Stock Price and Market Context

Shares of the biopharmaceutical company trade around $52.41, sitting comfortably higher than their 200-day moving average. Over the past year, the equity has moved between a low of $26.99 and a high of $55.67. This performance reflects steady interest in the healthcare firm's portfolio of specialty medicines.

Wall Street Analyst Updates

Wall Street firms have continued adjusting their views on the drug maker through the late summer and early fall. On September 22, 2026, RBC Capital reiterated its Outperform rating with a price target of $56.00. On the same day, Baird maintained an Outperform rating while lifting its target to $61.00. Earlier, on September 21, 2026, Needham reiterated its Buy rating with a $62.00 price target. Across 17 analyst opinions, the stock currently carries a consensus buy recommendation alongside a mean price target of $56.65.

Inside Alkermes Operations

Headquartered in Dublin, Ireland, Alkermes focuses on developing medicines for complex central nervous system disorders and addiction. Its commercial lineup includes treatments for schizophrenia, alcohol dependence, and opioid dependence, alongside extended-release offerings for neurological conditions. The company works to address unmet medical needs through both proprietary research and collaborative partnerships with major pharmaceutical players.

Looking Ahead for Alkermes

Market participants will want to watch for the company's next earnings report scheduled for October 28, 2026. Future regulatory filings will also reveal whether other large asset managers followed Loomis Sayles in trimming their positions or chose to build new stakes. Remember that 13F reports look backward at holdings from the end of the reporting period and might not reflect current portfolio decisions.